CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in CNS Pharmaceuticals, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +4 vs. Q3 2021
- Shares held
- 1.18M
- +207.3K (+21.4%) vs. Q3 2021
- Total value
- $828.0K
- −$609.0K (−42.4%) vs. Q3 2021
- New holders
- 7
- 3 more added
- Sold out
- 3
- 4 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNSP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.34M |
| Q1 2026 | 12 | $348.7K |
| Q4 2025 | 10 | $652.4K |
| Q3 2025 | 8 | $221.5K |
| Q2 2025 | 11 | $421.8K |
| Q1 2025 | 7 | $55.2K |
| Q4 2024 | 21 | $297.3K |
| Q3 2024 | 14 | $75.3K |
| Q2 2024 | 10 | $227.8K |
| Q1 2024 | 19 | $351.0K |
| Q4 2023 | 16 | $425.3K |
| Q3 2023 | 12 | $131.7K |
| Q2 2023 | 12 | $234.4K |
| Q1 2023 | 13 | $190.5K |
| Q4 2022 | 10 | $335.0K |
| Q3 2022 | 21 | $232.0K |
| Q2 2022 | 23 | $343.5K |
| Q1 2022 | 20 | $589.0K |
| Q4 2021 | 24 | $828.0K |
| Q3 2021 | 20 | $1.44M |
| Q2 2021 | 20 | $2.64M |
| Q1 2021 | 19 | $3.04M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding CNS Pharmaceuticals, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 177 | $0 | 0.00% | −4,709−96.4% | Reduced |
| Gradient Investments LLC | 200 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 10 | $0 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 25 | $0 | 0.00% | +25 | New |
| Migdal Insurance & Financial Holdings Ltd. | 1,283 | $1.00K | 0.00% | −775−37.7% | Reduced |
| Capital Analysts, LLC | 1,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| Global Retirement Partners, LLC | 1,000 | $1.00K | 0.00% | +1,000 | New |
| CoreCap Advisors, LLC | 800 | $1.00K | 0.00% | +800 | New |
| UBS Group AG | 3,653 | $3.00K | 0.00% | +3,653 | New |
| Morgan Stanley | 5,500 | $4.00K | 0.00% | −13−0.2% | Reduced |
| Wells Fargo & Company | 12,103 | $8.00K | 0.00% | −1,742−12.6% | Reduced |
| Alpha Cubed Investments, LLC | 11,000 | $8.00K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 11,513 | $8.00K | 0.00% | +11,513 | New |
| Tower Research Capital LLC (TRC) | 13,642 | $10.0K | 0.00% | +13,642 | New |
| State Street Corp | 17,988 | $13.0K | 0.00% | 00.0% | Unchanged |
| Commonwealth Equity Services, LLC | 20,000 | $14.0K | 0.00% | 00.0% | Unchanged |
| Cambridge Investment Research Advisors, Inc. | 25,250 | $18.0K | 0.00% | +14,000+124.4% | Added |
| Bank of New York Mellon Corp | 29,758 | $21.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 32,094 | $23.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 41,803 | $29.0K | 0.00% | +1,085+2.7% | Added |
| Citadel Advisors LLC | 81,934 | $58.0K | 0.00% | +60,721+286.2% | Added |
| Geode Capital Management, LLC | 107,262 | $75.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 147,700 | $104.0K | 0.00% | +147,700 | New |
| Vanguard Group Inc | 609,409 | $428.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 0 | $0 | 0.00% | −22,480−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −16,531−100.0% | Sold out |
| Sterling Financial Planning, Inc. | 0 | $0 | 0.00% | −600−100.0% | Sold out |